Combining panobinostat with αCD38 antibody in a CTCL mouse model significantly improved survival compared to the antibody alone, underscoring CD38’s therapeutic potential in CTCL. This evidence concerns the gene CD38 and primary cutaneous T-cell non-Hodgkin lymphoma.